COVID-19 mRNA Vaccine (Nucleoside Modified) (COVID-19 Vaccine Moderna) for the Prevention of COVID-19

Date of publication: May 28, 2021 Pursuant to the role of the Health Technology Assessment Council (HTAC) to develop coverage recommendations particularly in the selection and financing of COVID-19 vaccines using the Evaluation Framework set by the HTAC, this report presents all currently available evidence considered in the assessment of COVID-19 Vaccine Moderna. This assessment follows the continue reading : COVID-19 mRNA Vaccine (Nucleoside Modified) (COVID-19 Vaccine Moderna) for the Prevention of COVID-19

HTAC Recommends COVID-19 Vaccine Moderna Under Emergency Use for Reducing COVID-19 Risk in Persons Aged 18 and Older

Date of publication: May 28, 2021 Pursuant to the role of the Health Technology Assessment Council (HTAC) to develop coverage recommendations particularly in the selection and financing of COVID-19 vaccines using the Evaluation Framework set by the HTAC, this report presents all currently available evidence considered in the assessment of COVID-19 Vaccine Moderna. This assessment follows the continue reading : HTAC Recommends COVID-19 Vaccine Moderna Under Emergency Use for Reducing COVID-19 Risk in Persons Aged 18 and Older